m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00280)
Name
4-Butyrylamino-N-hydroxy-benzamide
Synonyms
CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262
    Click to Show/Hide
Status
Investigative
Structure
Formula
C11H14N2O3
InChI
1S/C11H14N2O3/c1-2-3-10(14)12-9-6-4-8(5-7-9)11(15)13-16/h4-7,16H,2-3H2,1H3,(H,12,14)(H,13,15)
InChIKey
WASGGDMUCRMECJ-UHFFFAOYSA-N
PubChem CID
11287488
TTD Drug ID
D05LLX
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Histone deacetylase 2 (HDAC2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Histone deacetylase 2 (HDAC2) is a therapeutic target for 4-Butyrylamino-N-hydroxy-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-Butyrylamino-N-hydroxy-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). [1], [2]
References
Ref 1 The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018 Feb;52(2):621-629. doi: 10.3892/ijo.2017.4219. Epub 2017 Dec 7.
Ref 2 Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. doi: 10.1021/jm0503749.